Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06781333 · ClinicalTrials.gov registry record · Phase 2
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
A Phase 2 study of Alzheimer Disease and Agitation in Dementia, sponsored by Bernard (Barry) Baumel.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT06781333 is a Phase 2 study of Alzheimer Disease and Agitation in Dementia that is actively recruiting participants, run by Bernard (Barry) Baumel. The registered enrollment target is 8 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06781333, a Phase 2 study of Alzheimer Disease and Agitation in Dementia, is actively recruiting participants, sponsored by Bernard (Barry) Baumel.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to test if adding one infusion of mesenchymal stem cells to the current treatment with antipsychotic medication may help control behavioral problems in people with a diagnosis of moderate to severe Alzheimer's disease.
Conditions Studied
Interventions
- BIOLOGICAL hMSC
Study Locations (1)
Florida
- University of Miami Department of Neurology - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2026-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06781333
The ClinicalTrials.gov registry entry for NCT06781333 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The listed sponsor is Bernard (Barry) Baumel, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which hMSC is the first listed.
NCT06781333 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06781333 about?
NCT06781333 is a clinical study titled "Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.". The purpose of this research study is to test if adding one infusion of mesenchymal stem cells to the current treatment with antipsychotic medication may help control behavioral problems in people with a diagnosis of moderate to severe Alzheimer's disease.
What is the current status of trial NCT06781333?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2025-04-29. Estimated completion is 2026-06-15.
What conditions does trial NCT06781333 study?
This clinical trial studies the following conditions: Alzheimer Disease, Agitation in Dementia.
What interventions are being tested in trial NCT06781333?
The interventions under investigation include: hMSC (BIOLOGICAL).
Who is sponsoring clinical trial NCT06781333?
This trial is sponsored by Bernard (Barry) Baumel, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06781333 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.